NEW
YORK, June 18, 2024 /PRNewswire/ -- The global
human combination vaccines market size is estimated to grow
by USD 7.02 billion from 2024-2028,
according to Technavio. The market is estimated to grow at a CAGR
of 8.69% during the forecast
period. Increasing antiviral drug resistance is
driving market growth, with a trend towards threat from
bioterrorism. However, consolidation of different immunization
schedules poses a challenge. Key market players include
Abbott Laboratories, Arabio, Bharat Biotech., Zydus Lifesciences
Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc,
Grifols SA, LG Corp., Meiji Holdings Co. Ltd., Merck and Co. Inc.,
Mitsubishi Chemical Group Corp., Panacea Biotec Ltd., Pfizer Inc.,
PT Bio Farma, Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda
Pharmaceutical Co. Ltd., Walvax Biotechnology Co. Ltd., and
Biological E. Ltd..
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Type (Inactivated
vaccine and Live attenuated vaccine), Channel (Hospitals,
Retailers, and Online), and Geography (North America, Europe, Asia,
and Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Abbott Laboratories,
Arabio, Bharat Biotech., Zydus Lifesciences Ltd., CSL Ltd., Daiichi
Sankyo Co. Ltd., GlaxoSmithKline Plc, Grifols SA, LG Corp., Meiji
Holdings Co. Ltd., Merck and Co. Inc., Mitsubishi Chemical Group
Corp., Panacea Biotec Ltd., Pfizer Inc., PT Bio Farma, Sanofi SA,
Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd.,
Walvax Biotechnology Co. Ltd., and Biological E. Ltd.
|
Key Market Trends Fueling Growth
The global human combination vaccines market is experiencing
significant growth due to the increasing threat of bioterrorism.
With the emergence of new contagious diseases, there is a pressing
need for effective vaccines to combat potential outbreaks.
Developed nations are taking proactive measures to address this
issue, leading to increased research and development in this area.
A bioterrorism-induced outbreak could result in mass vaccinations,
thereby driving market demand. Key players in the industry are
focusing on producing combination vaccines against potential
bioterrorism agents to meet this growing need.
The Human Combination Vaccines market is experiencing
significant growth due to the increasing demand for effective
preventive measures against various diseases. The use of
combination vaccines, which provide protection against multiple
diseases with a single dose, is a trending approach in this market.
Technologies like Adjuvants and Conjugate Technology are key
factors driving the development of new combination vaccines.
Companies are focusing on producing Pediatric and Adult vaccines
for diseases such as Diphtheria, Tetanus, Pertussis, Hepatitis B,
and Polio. The market is also witnessing an increase in the
production of Vaccines for diseases like Measles, Mumps, Rubella,
and Chickenpox. The use of advanced technologies like Microbial
Reactor Technology and Vector Technology is expected to further
boost the market growth. The market for Vaccines is expected to
continue its upward trend in the coming years.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
• The global
human combination vaccines market faces challenges due to the
consolidation of immunization schedules. This can lead to decreased
immunogenicity or overdosing of vaccine components. For example,
the Hep B vaccine, which ideally requires three doses, is often
given in combination with DTaP. This results in an unnecessary
fourth dose and reduced Hep B vaccine effectiveness. Research shows
that the immunogenicity of Hep B significantly decreases when given
in combination form. To ensure sufficient antibody production and
reduce the risk of hepatitis infection, separate administration of
Hep B is recommended. These factors may hinder market growth during
the forecast period.
• The Human
Combination Vaccines market faces several challenges. The
production of these vaccines requires complex processes, involving
the combination of multiple vaccines in one dose. This increases
the cost and complexity of manufacturing. Additionally, ensuring
the safety and efficacy of these vaccines is a significant
challenge. Regulatory bodies impose strict guidelines, requiring
extensive testing and clinical trials. Furthermore, logistics and
distribution pose challenges due to the need for proper storage and
transportation conditions. Lastly, affordability is a major
concern, as these vaccines can be expensive for many individuals
and healthcare systems. Despite these challenges, the Human
Combination Vaccines market continues to grow, driven by the
benefits of increased protection against multiple diseases with a
single vaccine.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This human combination vaccines market report extensively covers
market segmentation by
- Type
- 1.1 Inactivated vaccine
- 1.2 Live attenuated vaccine
- Channel
- 2.1 Hospitals
- 2.2 Retailers
- 2.3 Online
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Inactivated vaccine- The inactivated segment
leads the global human combination vaccines market due to its
better tolerability and fewer complications. Inactivated vaccines,
which use dead pathogens, are safer for immunocompromised patients
and provide short-term protection with a weak immune response. They
are produced using heat and chemicals and are easy to store and
transport. Despite advantages, high costs are a concern for
large-scale immunization programs. The COVID-19 pandemic disrupted
vaccine demand in the first half of 2020 but initiatives to restore
services have positively impacted the market.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2018 - 2022) - Download a Sample Report
Research Analysis
The Human Combination Vaccines market encompasses the production
and distribution of vaccines that contain multiple antigens to
protect against various diseases caused by different organisms.
Combination vaccines, such as MMR (Measles, Mumps, and Rubella) and
Pentacel (Diphtheria, Tetanus, Acellular Pertussis, Inactivated
Poliovirus, and Hepatitis B), offer the advantage of reducing the
number of vaccine shots required. However, the production and
logistical constraints of these vaccines pose challenges. Side
effects, although rare, are a concern for medical practitioners and
the public. Regulatory policies play a crucial role in ensuring
vaccine safety and efficacy. The demand for vaccination has surged
due to the coronavirus pandemic, with increasing infected cases and
death rates. Bioterrorism is another factor driving the need for
combination vaccines to protect against multiple diseases. The
immune system relies on these vaccines to build immunity against
infections caused by inactivated virus strains. Government efforts
and vaccination programs are essential in addressing the challenges
and ensuring the availability and accessibility of these vital
health interventions. The MMRV vaccine, a combination of MMR and
Varicella (Chickenpox) vaccine, is another important addition to
the market.
Market Research Overview
The Human Combination Vaccines market refers to the production
and distribution of vaccines that contain two or more antigens to
protect against multiple diseases. These vaccines are essential in
preventing the spread of infectious diseases and reducing the
global health burden. The market is driven by factors such as
increasing population, rising awareness about vaccines, and
technological advancements in vaccine development. The market also
faces challenges like high production costs and logistical issues
in distributing vaccines to remote areas. The market for Human
Combination Vaccines is expected to grow significantly in the
coming years due to the increasing demand for vaccines that offer
protection against multiple diseases with a single dose. The market
caters to various sectors, including public health organizations,
hospitals, and research institutions. The market is segmented based
on vaccine type, application, and region.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Type
-
- Inactivated Vaccine
- Live Attenuated Vaccine
- Channel
-
- Hospitals
- Retailers
- Online
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/human-combination-vaccines-market-size-is-set-to-grow-by-usd-7-02-billion-from-2024-2028--increasing-antiviral-drug-resistance-to-boost-the-market-growth-technavio-302175343.html
SOURCE Technavio